Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accounts Payables: 2019-2024

Historic Accounts Payables for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $9.6 million.

  • BridgeBio Pharma's Accounts Payables rose 39.95% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 39.95%. This contributed to the annual value of $9.6 million for FY2024, which is 9.73% down from last year.
  • BridgeBio Pharma's Accounts Payables amounted to $9.6 million in FY2024, which was down 9.73% from $10.7 million recorded in FY2023.
  • BridgeBio Pharma's Accounts Payables' 5-year high stood at $11.9 million during FY2021, with a 5-year trough of $8.9 million in FY2020.
  • Its 3-year average for Accounts Payables is $10.6 million, with a median of $10.7 million in 2023.
  • Per our database at Business Quant, BridgeBio Pharma's Accounts Payables soared by 32.86% in 2021 and then dropped by 9.73% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Accounts Payables (Yearly) stood at $8.9 million in 2020, then skyrocketed by 32.86% to $11.9 million in 2021, then decreased by 2.74% to $11.6 million in 2022, then decreased by 7.81% to $10.7 million in 2023, then dropped by 9.73% to $9.6 million in 2024.